01Identity
What is it?
The product may be a defined deoxycholic-acid medicine or another formulation; different active ingredients and excipients must never be treated as equivalent.
Injection Lipolysis and Body Contouring · Aesthetic Medicine
Injection Lipolysis and Body Contouring · Aesthetic Medicine
Injection Lipolysis and Body Contouring
Injection lipolysis is not a generic body-slimming treatment. Deoxycholic-acid products, phospholipid-containing mixtures and other injections have different compositions, legal status, evidence and tissue effects; authorisation for one small area cannot be transferred to the body.
The first task is to distinguish subcutaneous fat from skin laxity, muscle, visceral fat, swelling or another medical finding. No body-contouring injection is selected remotely.
Quick Orientation
Identity · composition · preparation · route
The treatment name is only the start of the medical description.
A responsible discussion identifies the exact preparation or device, how it was made, where it is intended to act and which clinical question is being assessed.
02Production
How is it prepared?
Manufacturer, sterile manufacture, concentration, vial, batch, storage and authorisation for the proposed area are reviewed before use.
03Route
How does it reach tissue?
The intended route is local injection into a defined subcutaneous fat compartment. Dermal, intramuscular or vascular exposure can cause tissue injury.
04Target
What is the clinical target?
Only a small, clearly defined subcutaneous fat question is considered; weight loss, visceral fat and general body reshaping are different clinical aims.
Method Boundary
A prescription medicine or mixture, not a generic fat-dissolving class
Active ingredient, licensed region and target tissue define injection lipolysis.
The intended role, product identity and target tissue stay visible so unlike procedures are not presented as one interchangeable class.
What may be considered
- Assess a defined product for a defined authorised or disclosed off-label context
- Distinguish subcutaneous fat from laxity and other anatomy
- Document the target area and a realistic contour endpoint
- Compare injection with observation, weight management or surgery
What must not be inferred
- Treat all lipolysis mixtures as one medicine
- Transfer submental evidence to abdomen, limbs or another region
- Provide weight loss or whole-body contouring
- Guarantee even reduction, skin tightening or permanence
Unclear product identity, an unsupported anatomical area or an inability to distinguish the target fat layer is a reason not to inject.
Medical Suitability
Clinical question before method selection
Five checks precede any personal decision.
The examination distinguishes fat, skin, muscle, glands, scars and other causes of contour. The exact medicine and regional authorisation are then reviewed.
- 01
Confirm the finding
Local subcutaneous fat is separated from skin laxity, hernia, oedema, lymph nodes, gland or muscle-related contour.
- 02
Map vulnerable anatomy
Nerves, vessels, glands, previous surgery, scars and the thickness of the target layer affect safety.
- 03
Verify the medicine
Active ingredient, formulation, manufacturer, batch, authorised region and any off-label status are disclosed.
- 04
Review health factors
Swallowing problems, infection, bleeding risk, pregnancy or breastfeeding and relevant illness or medicines are assessed.
- 05
Compare alternatives
Observation, weight management, non-injectable contouring or surgery may better fit the actual problem.
Product and Treatment Path
Traceability without a public injection recipe
Medicine, anatomical region and target layer must align.
A recognised active ingredient does not make every body area appropriate. Product labelling and area-specific evidence remain central.
01Medicine
Product and authorisation
The exact medicine is checked for composition, manufacturer and permitted indication in the relevant jurisdiction.
- Verify active ingredient and vial
- Record batch and storage
- Disclose licensed or off-label context
02Anatomy
Fat compartment and boundaries
The target layer and vulnerable adjacent structures are assessed in person without publishing an injection map.
- Confirm subcutaneous target
- Review scars and prior procedures
- Protect nerves, vessels and glands
03Follow-up
Inflammation and contour review
The expected local inflammatory course is separated from tissue injury and the later contour endpoint.
- Record region and exposure
- Set early safety review
- Predefine stop and reassessment criteria
This information does not provide a dose, area grid, injection spacing, depth, point, needle, anaesthetic plan or session schedule.
Evidence and Limits
Read the data at product and indication level
Evidence and authorisation are anatomical-area specific.
Randomised trials and regulatory review for a defined deoxycholic-acid product in submental fat do not establish safety or effectiveness elsewhere or for other mixtures.
Match the medicine
Data from one defined formulation cannot be transferred to another active ingredient or mixture.
Match the region
Submental anatomy, endpoints and adverse events are not a proxy for abdomen, arms or thighs.
Read the comparator
A contour-rating change is not the same as weight loss, metabolic benefit or general body reshaping.
Keep harms visible
Nerve injury, dysphagia, ulceration, necrosis, infection and uneven contour remain part of the evidence.
A market term such as fat dissolving does not establish authorisation, area-specific effectiveness, systemic safety or a predictable personal contour.
Individual Plan
One indication · one traceable intervention · one review point
A local fat question requires a local, anatomy-specific plan.
The exact medicine, area, target layer, realistic endpoint, alternatives and stop rule are documented before any treatment decision.
Document the anatomy
Baseline examination and photographs separate fat thickness, skin quality, asymmetry and other causes.
Verify product status
The licensed region and any off-label proposal are stated plainly rather than hidden in package language.
Plan early review
Swelling, pain, nerve function, swallowing and skin circulation require a defined safety route.
Stop before escalation
Tissue injury, neurological symptoms, infection or an unacceptable contour response ends automatic continuation.
Course and Follow-Up
Expected reaction · adverse effect · clinical endpoint
Inflammation may be expected; tissue damage is not an endpoint.
Swelling, bruising, pain, numbness and firmness can be prominent. Their presence does not prove an appropriate dose or later contour benefit.
- 01Treatment day
Record the exposure
Medicine, batch, region, route and immediate skin and neurological findings are documented.
- 02Early safety
Review function and skin
Asymmetrical smile, weakness, swallowing difficulty, severe pain, blistering or colour change needs prompt assessment.
- 03Later review
Allow inflammation to settle
Contour is not judged while marked swelling or induration remains.
- 04Decision
Apply the stop rule
Necrosis, infection, nerve injury, persistent irregularity or no meaningful benefit blocks routine repetition.
Risks and Alternatives
Material, anatomy and route shape risk
The target is close to structures that must not be injured.
Expected local reactions coexist with clinically important risks from the medicine, tissue layer and neighbouring anatomy.
01Common
Local reaction
Swelling, pain, bruising, numbness, redness and induration may be substantial.
02Regional
Anatomical injury
Nerve injury, asymmetry, dysphagia, vascular injury and damage to glands or muscle may occur.
03Serious
Tissue and systemic harm
Ulceration, necrosis, infection, alopecia, contour irregularity and unexpected systemic effects require review.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Severe or increasing pain, blistering, skin colour change, facial weakness, swallowing difficulty, fever or spreading inflammation requires immediate local medical assessment. Alternatives may include observation, weight-management support, a diagnosis-led non-injectable approach or surgical body contouring.
Istanbul and Follow-Up
A treatment decision must remain reviewable after travel
Assessment, product records and a local safety route travel together.
International care is not reduced to a treatment day. The in-person examination, exact intervention, early review and later endpoint are connected before departure.
01Before travel
Organise the question
History, previous procedures and the specific injection lipolysis and body contouring question prepare the visit without confirming suitability.
02In Istanbul
Examine in person
Anatomy, tissue, active disease, product or device status, risks and alternatives are reviewed together.
03Treatment day
Keep exact records
Product or device identity, batch where relevant, treated region, route and observations remain traceable.
04After return
Arrange review
Expected reactions, stop criteria, local medical access and the later clinical endpoint are agreed before return travel.
The Doctor Aslan Approach
Product-specific, anatomy-led and reversible in decision-making
A body area is never treated as an extension of a labelled chin indication.
The medicine, authorised area, target fat and vulnerable anatomy are reviewed as one decision. Off-label use, if considered at all, is stated explicitly.
Diagnose the contour
Fat, laxity, muscle and other causes are separated before a method is discussed.
Name the medicine
Composition, licence and batch replace a generic fat-dissolving label.
Respect the region
Area-specific evidence and anatomy prevent casual transfer across the body.
Prepare to stop
Neurological, vascular, infectious or contour concerns end automatic repetition.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about injection lipolysis and body contouring; no personal protocol or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Injection Lipolysis and Body Contouring?+
Injection Lipolysis and Body Contouring is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Injection Lipolysis and Body Contouring?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Confirm the tissue · verify the medicine · disclose the region